Ash Stringer August 14th, 2019 App, Exclusive, News, Top Story When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp.... Read more
Joy Crosby August 9th, 2019 App, Exclusive, News, Top Story As an emerging and relatively new line of business, cannabis has already proven itself to be a powerhouse of a market. The global cannabis industry’s revenue ballooned to US $12.2 billion in 2018, with predictions that it will reach... Read more
Ryan Allway August 2nd, 2019 Exclusive, News, Top Story, Uncategorized Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission,... Read more
Synthetic Cannabinoids: The New Age of Medical Marijuana
July 22, 2019
Ryan Allway July 22nd, 2019 App, Exclusive, News, Top News Believe it or not, the world’s first blockbuster drug is still one of the most commonly used today. Acetylsalicylic acid, better known as Aspirin®, is a synthetic derivative of the natural substance salicylic acid, an extract from the bark... Read more
VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical candidate for... Read more
Halo Labs Announces Repricing of Convertible Debenture Units and An Increase in The Expected Size of The Offering
March 15, 2019
Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTC: AGEEF, Germany: A9KN) announces that it has agreed to amend the terms of its previously announced “best efforts” offering (the “Offering”) of convertible debenture units (the “Convertible Debenture Units”) to lower the conversion price at which the convertible debentures are... Read more
NexTech Raises $1,464,600 From $0.50 Warrant Conversion
March 8, 2019
Ryan Allway March 8th, 2019 News, Top News New York, New York and Toronto, Ontario–(Newsfile Corp. – March 8, 2019) – NexTech AR Solutions (OTC Pink: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”), a technology and emerging commercial growth company focused on bringing augmented reality (“AR”) to... Read more
CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Gaining Appeal in Cannabis Edibles with DehydraTECH
February 1, 2019
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) — via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Outside Investment, New Technology Support Growing Cannabis Industry,” featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). To hear the CannabisNewsAudio version, visit: http://cnw.fm/uXf6S To read the full editorial, visit: http://cnw.fm/H3q7r DehydraTECH... Read more
VANCOUVER, British Columbia, Feb. 01, 2019 (GLOBE NEWSWIRE) — The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) (Frankfurt:YG3) is pleased to announce that the OTCQB Venture Market has approved the listing of the company’s shares on the OTCQB market under the ticker symbol “BOSQF” and that trading will begin at market open... Read more
Aleafia Health Study Indicates 45% of Patients End Benzodiazepine Use Following Medical Cannabis Treatment
January 25, 2019
Ryan Allway January 25th, 2019 News, Top News Authors Leveraged Aleafia’s 10 Million Point Medical Cannabis Dataset TORONTO, Jan. 25, 2019 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), announces today what it believes to be the first study reporting... Read more
